1. Home
  2. PCRX vs RPD Comparison

PCRX vs RPD Comparison

Compare PCRX & RPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PCRX
  • RPD
  • Stock Information
  • Founded
  • PCRX 2006
  • RPD 2000
  • Country
  • PCRX United States
  • RPD United States
  • Employees
  • PCRX N/A
  • RPD N/A
  • Industry
  • PCRX Biotechnology: Pharmaceutical Preparations
  • RPD Computer Software: Prepackaged Software
  • Sector
  • PCRX Health Care
  • RPD Technology
  • Exchange
  • PCRX Nasdaq
  • RPD Nasdaq
  • Market Cap
  • PCRX 1.2B
  • RPD 1.3B
  • IPO Year
  • PCRX 2011
  • RPD 2015
  • Fundamental
  • Price
  • PCRX $26.86
  • RPD $19.44
  • Analyst Decision
  • PCRX Buy
  • RPD Hold
  • Analyst Count
  • PCRX 6
  • RPD 19
  • Target Price
  • PCRX $30.00
  • RPD $27.00
  • AVG Volume (30 Days)
  • PCRX 592.7K
  • RPD 709.0K
  • Earning Date
  • PCRX 11-05-2025
  • RPD 11-05-2025
  • Dividend Yield
  • PCRX N/A
  • RPD N/A
  • EPS Growth
  • PCRX N/A
  • RPD N/A
  • EPS
  • PCRX N/A
  • RPD 0.43
  • Revenue
  • PCRX $705,848,000.00
  • RPD $855,361,000.00
  • Revenue This Year
  • PCRX $7.36
  • RPD $2.75
  • Revenue Next Year
  • PCRX $10.07
  • RPD $3.21
  • P/E Ratio
  • PCRX N/A
  • RPD $45.07
  • Revenue Growth
  • PCRX 2.25
  • RPD 4.67
  • 52 Week Low
  • PCRX $13.04
  • RPD $17.83
  • 52 Week High
  • PCRX $27.64
  • RPD $44.48
  • Technical
  • Relative Strength Index (RSI)
  • PCRX 61.04
  • RPD 41.49
  • Support Level
  • PCRX $25.63
  • RPD $19.36
  • Resistance Level
  • PCRX $27.11
  • RPD $21.26
  • Average True Range (ATR)
  • PCRX 0.96
  • RPD 0.62
  • MACD
  • PCRX -0.05
  • RPD -0.03
  • Stochastic Oscillator
  • PCRX 68.80
  • RPD 4.96

About PCRX Pacira BioSciences Inc.

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

About RPD Rapid7 Inc.

Founded in 2000, Rapid7 is a cybersecurity company that began providing vulnerability management solutions. It has, however, expanded its portfolio to provide extended detection and response; security information and event management; cloud security, threat intelligence, and application security; and security orchestration, automation, and response. The Boston-based company went public in 2015.

Share on Social Networks: